These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31559570)

  • 21. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5.
    Gregg LP; Hedayati SS; Yang H; Van Buren PN; Banerjee S; Navaneethan SD; Virani SS; Winkelmayer WC; Alvarez CA
    Hypertension; 2021 Mar; 77(3):948-959. PubMed ID: 33423525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should reduction of increased short-term blood pressure variability be a target of antihypertensive therapy?
    Mulè' G; Sorce A; Vario MG; Giambrone M; Cottone S
    J Clin Hypertens (Greenwich); 2021 Jun; 23(6):1162-1164. PubMed ID: 33538054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure variability: epidemiological and clinical issues.
    Krzych ŁJ; Bochenek A
    Cardiol J; 2013; 20(2):112-20. PubMed ID: 23558867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of blood pressure variability by combination therapy in spontaneously hypertensive rats.
    Xie HH; Shen FM; Xu LP; Han P; Miao CY; Su DF
    J Hypertens; 2007 Nov; 25(11):2334-44. PubMed ID: 17921830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study.
    Hermida RC
    Chronobiol Int; 2007; 24(4):749-75. PubMed ID: 17701685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same?
    Smith DH
    Am J Cardiovasc Drugs; 2007; 7(6):413-22. PubMed ID: 18076208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target.
    Parati G; Ochoa JE; Lombardi C; Bilo G
    Curr Hypertens Rep; 2015 Apr; 17(4):537. PubMed ID: 25790801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term blood pressure variability outweighs average 24-h blood pressure in the prediction of cardiovascular events in hypertension of the young.
    Palatini P; Saladini F; Mos L; Fania C; Mazzer A; Cozzio S; Zanata G; Garavelli G; Biasion T; Spinella P; Vriz O; Casiglia E; Reboldi G
    J Hypertens; 2019 Jul; 37(7):1419-1426. PubMed ID: 30882599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
    Petrella R; Michailidis P
    Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertension, Blood Pressure Variability, and Target Organ Lesion.
    Irigoyen MC; De Angelis K; Dos Santos F; Dartora DR; Rodrigues B; Consolim-Colombo FM
    Curr Hypertens Rep; 2016 Apr; 18(4):31. PubMed ID: 27002717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects on 24-hour blood pressure variability of ace-inhibition and calcium channel blockade as monotherapy or in combination.
    Parati G; Castiglioni P; Omboni S; Faini A
    Sci Rep; 2018 Sep; 8(1):13779. PubMed ID: 30213981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic target and clinical impact of day-to-day blood pressure variability in hypertensive patients with covid-19.
    Jagannatha GNP; Yasmin AAADA; Pradnyana IWAS; Kamardi S; Pradnyaandara IGBMA; Pangkahila EE; Perkasa GOBD; Wibawa IBS
    Hypertens Res; 2023 Jan; 46(1):165-174. PubMed ID: 36280737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study.
    Zhang Y; Agnoletti D; Safar ME; Blacher J
    Hypertension; 2011 Aug; 58(2):155-60. PubMed ID: 21747047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications.
    Ayala DE; Hermida RC; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):340-52. PubMed ID: 23077973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium channel blockers in cardiovascular pharmacotherapy.
    Godfraind T
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):501-15. PubMed ID: 24872348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood pressure variability, cardiovascular risk, and risk for renal disease progression.
    Parati G; Ochoa JE; Bilo G
    Curr Hypertens Rep; 2012 Oct; 14(5):421-31. PubMed ID: 22903810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment and management of blood-pressure variability.
    Parati G; Ochoa JE; Lombardi C; Bilo G
    Nat Rev Cardiol; 2013 Mar; 10(3):143-55. PubMed ID: 23399972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.